1. Home
  2. RIGL vs EMX Comparison

RIGL vs EMX Comparison

Compare RIGL & EMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • EMX
  • Stock Information
  • Founded
  • RIGL 1996
  • EMX N/A
  • Country
  • RIGL United States
  • EMX Canada
  • Employees
  • RIGL N/A
  • EMX N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • EMX
  • Sector
  • RIGL Health Care
  • EMX
  • Exchange
  • RIGL Nasdaq
  • EMX Nasdaq
  • Market Cap
  • RIGL 335.5M
  • EMX 338.0M
  • IPO Year
  • RIGL 2000
  • EMX N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • EMX $3.65
  • Analyst Decision
  • RIGL Buy
  • EMX Strong Buy
  • Analyst Count
  • RIGL 5
  • EMX 2
  • Target Price
  • RIGL $38.20
  • EMX $5.38
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • EMX 447.8K
  • Earning Date
  • RIGL 08-05-2025
  • EMX 08-11-2025
  • Dividend Yield
  • RIGL N/A
  • EMX N/A
  • EPS Growth
  • RIGL N/A
  • EMX N/A
  • EPS
  • RIGL 5.43
  • EMX 0.04
  • Revenue
  • RIGL $267,921,000.00
  • EMX $29,864,000.00
  • Revenue This Year
  • RIGL $59.93
  • EMX $11.08
  • Revenue Next Year
  • RIGL N/A
  • EMX $3.72
  • P/E Ratio
  • RIGL $7.15
  • EMX $80.97
  • Revenue Growth
  • RIGL 105.62
  • EMX N/A
  • 52 Week Low
  • RIGL $12.66
  • EMX $1.59
  • 52 Week High
  • RIGL $43.72
  • EMX $3.66
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • EMX 74.62
  • Support Level
  • RIGL $39.00
  • EMX $3.04
  • Resistance Level
  • RIGL $42.08
  • EMX $3.37
  • Average True Range (ATR)
  • RIGL 2.32
  • EMX 0.12
  • MACD
  • RIGL -0.37
  • EMX 0.03
  • Stochastic Oscillator
  • RIGL 53.26
  • EMX 97.58

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About EMX EMX Royalty Corporation (Canada)

EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.

Share on Social Networks: